Empagliflozin
- OralEmpagliflozinJardiance
Mechanism of Action
- Inhibits sodium-glucose co-transporter 2 (SGLT2) in the proximal tubules, resulting in reduced glucose reabsorption and glycosuria.
Clinical Use
- Indications
- Glycaemic control in type 2 diabetes mellitus
- Prevention of cardiovascular events in patients with cardiovascular disease and type 2 diabetes
- Adverse Effects
- Genitourinary infections (due to glycosuria)
- Polyuria